Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a Seattle-based life sciences company built around immune-system sequencing and computational biology. It develops clinical diagnostics and research tools that read T-cell and B-cell receptor signals from blood and tissue samples, then uses those data to support cancer monitoring, immune profiling, and drug discovery. The company’s commercial platform is anchored by clonoSEQ, an MRD test used in hematologic cancers, while its research and collaboration business includes Adaptive Immunosequencing and immune medicine programs. Adaptive also applies AI and machine learning to its immune receptor database to discover targets and characterize disease biology. The business sits at the intersection of diagnostics, research services, and therapeutic discovery, with revenue tied to clinical adoption, biopharma collaborations, and reimbursement coverage.

−14,8 %

74,2 %

−21,5 %

+54,8 %

3.34

3.23

— Adaptive Biotechnologies Corp
%
Clinical diagnostics65% Commercial MRD testing and related clinical reporting for hematologic cancer monitoring, primarily through clonoSEQ.
Research services20% Sequencing and analysis services sold to biopharmaceutical companies and academic institutions for discovery and translational research.
Immune medicine collaborations15% Partner-funded R&D support, collaboration revenue, and milestone-linked programs such as the Genentech agreement.

Adaptive sells to a mix of clinical, research, and biopharmaceutical customers. Its clinical customer base includes...

  • Clinical MRD customersprimary

    Physicians and health systems ordering clonoSEQ for disease monitoring in hematologic malignancies, with reimbursement and clinical utility driving use.

  • Biopharmaceutical customersprimary

    Drug developers buying MRD sample testing, sequencing services, and platform access to support therapeutic development and biomarker discovery.

  • Academic and research institutionssecondary

    Universities and research centers using Adaptive Immunosequencing and MRD services for translational research and investigator-led studies.

  • Immune medicine collaboratorssecondary

    Partners such as Genentech that fund R&D support and collaboration work to advance TCR-based and other immune medicine programs.

Adaptive is headquartered in Seattle, Washington and operates primarily as a U.S.-centric business...

  • •Headquartered in Seattle, Washington
  • •U.S. clinical market is the core revenue base for clonoSEQ
  • •Coverage expansion across Medicare and private payors supports U.S. adoption
  • •International technology transfer sites contribute a smaller portion of MRD activity
  • •Biopharma collaborations can be global, but revenue is still U.S.-weighted

Adaptive’s strategy is to expand clonoSEQ penetration in covered patient populations while broadening reimbursement and...

01
Expand MRD clinical testing volumeshort-term

Higher test volume improves operating leverage and strengthens the core clinical diagnostics franchise.

02
Build immune medicine discovery capabilitiesmedium-term

A larger data and analytics engine can create new research, licensing, and therapeutic opportunities beyond MRD.

03
Replace and diversify collaboration revenuemedium-term

Reducing dependence on any single partner program lowers revenue volatility after the Genentech wind-down.

Adaptive faces execution risk in a highly competitive and rapidly changing biotechnology market, where diagnostics,...

high

Genentech agreement termination and wind-down

Management disclosed that the agreement has been terminated and may materially affect business and financial condition because it had supported Immune Medicine revenue.

Scope
Immune Medicine collaboration revenue
Materiality
high
high

Reimbursement and coverage dependence

Clinical MRD adoption depends on payor coverage and reimbursement rates, which directly affect test volume and collectible revenue.

Scope
clonoSEQ clinical revenue
Materiality
high
medium

Competitive pressure in MRD and immune medicine

The company competes with flow cytometry, ctDNA, and other emerging blood-based monitoring tools, which can limit market share and pricing power.

Scope
Clinical diagnostics and research services
Materiality
high
medium

Supplier and laboratory operations risk

The business depends on accurate lab execution and some single or limited suppliers for equipment and materials, creating operational fragility.

Scope
Testing throughput and cost of revenue
Materiality
medium
medium

Regulatory and AI governance risk

The company uses AI/ML and operates in a heavily regulated industry, so privacy, validation, and compliance failures could impair commercialization.

Scope
Platform development and data use
Materiality
medium
Revenue recognition across multiple contract types
Can materially shift revenue between quarters and affect gross margin
Deferred revenue and cumulative catch-up adjustments
Affects reported revenue timing and volatility
Collectability and reimbursement estimates
Can change reported clinical revenue and receivables
Goodwill and long-lived asset impairment
Potential non-cash charges to earnings
Purchase Agreement interest accretion
Affects net loss and liability measurement

Aptevo Therapeutics Inc.

APVO · Pharmaceutical Preparations

CytomX Therapeutics, Inc.

CTMX · Pharmaceutical Preparations

BIO-TECHNE Corp

TECH · Biological Products, (No Diagnostic Substances)

Aptose Biosciences Inc.

APTOF · Biological Products, (No Diagnostic Substances)

Calidi Biotherapeutics, Inc.

CLDI · Biological Products, (No Diagnostic Substances)

Tectonic Therapeutic, Inc.

TECX · Biological Products, (No Diagnostic Substances)

: 11/08/2026